IL1RA Mouse, His Active
Description
Biological Activity and Mechanism
IL1RA Mouse, His Active functions as a competitive inhibitor of IL-1α/β by binding to IL-1R type I (IL-1RI) with high affinity, preventing downstream pro-inflammatory signaling . Key findings include:
-
In vitro: Blocks IL-1β-induced NF-κB activation in immune cells and reduces IL-6 production .
-
In vivo:
Inflammation and Immunity Studies
-
Lipid-RNA Vaccine Toxicity: IL1RA Mouse, His Active mitigates systemic inflammation caused by RNA-LPX vaccines by balancing IL-1/IL-1ra ratios .
-
Sepsis Models: Administration reduces cytokine storms and improves survival in LPS-challenged mice .
Neurological Disorders
-
Epilepsy: Intracerebral infusion delays seizure onset and reduces ictal activity in bicuculline-induced models .
Autoimmune Diseases
-
Rheumatoid Arthritis (RA): Subcutaneous injection (1–2 mg/kg) decreases joint inflammation and erosions in mice .
Comparative Analysis with Human IL-1RA
Product Specs
IRAP, IL1F3, IL1RA, IL-1ra3, ICIL-1RA, IL1RN, IL1 inhibitor, IL-1ra, F630041P17Rik.
Escherichia Coli.
MGSSHHHHHH SSGLVPRGSH MGSHMRPSGK RPCKMQAFRI WDTNQKTFYL RNNQLIAGYL
QGPNIKLEEK IDMVPIDLHS VFLGIHGGKL CLSCAKSGDD IKLQLEEVNI TDLSKNKEED
KRFTFIRSEK GPTTSFESAA CPGWFLCTTL EADRPVSLTN TPEEPLIVTK FYFQEDQ
Q&A
Interleukin-1 Receptor Antagonist (IL1RA) Mouse Recombinant (His-Active) presents unique challenges and opportunities in immunological research. Below are structured FAQs addressing critical academic considerations, supported by experimental evidence from peer-reviewed methodologies and patent analyses.
What experimental validation methods confirm IL1RA Mouse bioactivity?
Methodological workflow:
-
Establish dose-response curve (0.1-100 ng/mL IL1RA)
-
Measure IL-2 production inhibition via ELISA (≥80% suppression indicates potency)
-
Validate specificity through receptor competition assays with IL-1 isoforms
Key validation parameters:
| Parameter | Specification | Source |
|---|---|---|
| Purity (RP-HPLC) | ≥98% | |
| Endotoxin level | <0.1 EU/μg | |
| Activity threshold | IC₅₀ ≤5 nM |
How to address batch variability in recombinant IL1RA preparations?
-
Implement orthogonal characterization:
What strategies resolve contradictory data in IL1RA-mediated inflammation models?
Multivariate approach:
| Factor | Rheumatoid Arthritis Model | Sepsis Model |
|---|---|---|
| Peak serum concentration | 1.2-2.8 μg/mL | 5-8 μg/mL |
| Dosing interval | Q12h | Continuous infusion |
| Synergistic agents | TNF-α inhibitors | AMPK activators |
Mechanistic considerations:
-
Tissue penetration varies by molecular format (17 kDa monomer vs. 45 kDa PEGylated forms)
-
Neutralizing antibody development observed in 12% of chronic models
What controls are essential for IL1RA specificity studies?
Required controls:
-
IL-1R1 knockout cell line parallel experiments
-
Cross-reactivity panel testing against IL-33/IL-36 receptors
Common pitfalls:
Product Science Overview
Interleukin-1 Receptor Antagonist (IL-1Ra) is a naturally occurring anti-inflammatory protein that plays a crucial role in modulating the immune response. It is part of the interleukin-1 (IL-1) cytokine family, which is involved in various inflammatory processes. The recombinant form of IL-1Ra, particularly the mouse version with an active His tag, is widely used in research to study its effects and potential therapeutic applications.
The mouse recombinant IL-1Ra is produced in Escherichia coli (E. coli) and is a single, non-glycosylated polypeptide chain. It consists of 177 amino acids, with a molecular mass of approximately 20 kDa. The protein is fused to a 25 amino acid His tag at the N-terminus, which facilitates its purification through chromatographic techniques .
IL-1Ra functions as an anti-inflammatory antagonist by inhibiting the activities of pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and interleukin-1 alpha (IL-1α). By binding to the IL-1 receptors without eliciting a signal, IL-1Ra effectively blocks the binding of IL-1α and IL-1β, thereby preventing their pro-inflammatory effects. This regulation is crucial in protecting the body from immune dysregulation and uncontrolled systemic inflammation triggered by various stimulatory agents, including pathogens .
The IL-1 cytokine family, including IL-1Ra, plays a significant role in the initiation and regulation of inflammatory responses. Dysregulation of IL-1 signaling can lead to chronic inflammatory diseases. IL-1Ra, along with other anti-inflammatory members of the IL-1 family such as IL-36Ra, IL-37, and IL-38, is highly expressed in the epidermis and is involved in controlling inflammatory responses in both human and mouse skin .
The recombinant form of IL-1Ra with an active His tag is extensively used in research to study its therapeutic potential in various inflammatory conditions. It is particularly valuable in investigating the mechanisms of immune regulation and the development of anti-inflammatory therapies. The His tag allows for easy purification and detection, making it a useful tool in experimental settings.
